Perinatal Reduced Blood Concentrations of Free Carnitine and Acylcarnitines in Infants with Cystic Fibrosis

Abstract

Objective Cystic fibrosis (CF) is a multisystemic inherited disease. The aim of this study was to determine free carnitine (FC) and acylcarnitine concentrations in CF newborns with various mutations of the CFTR gene perinatally.

Study Design FC/acylcarnitines were determined in dried blood spots via liquid chromatography-tandem mass spectrometry (LC-MS/MS) on the third day of life of full-term normal (n = 50) and CF (n = 28) newborns. For infants with elevated immunoreactive trypsinogen values, FC/acylcarnitines were quantified again 48 hours later, followed by mutational analysis of CFTR gene via Sanger sequencing.

Results Initial FC and sums of acylcarnitine concentrations were statistically significantly lower in CF patients than in controls and even lower 48 hours later. The mutations F508del and 621 + 1G > T were predominantly identified among CF patients.

Conclusion Low FC and acylcarnitine concentrations were measured perinatally in CF patients, for all CFTR mutations detected. Carnitine supplementation of breastfeeding mothers could be beneficial.

Keywords

cystic fibrosis - CFTR gene - acylcarnitines - newborn screening - fatty acids

Publication History

Received: 23 August 2019

Accepted: 25 November 2019

Article published online:
31 December 2019

• References

• 1 Riordan JR, Rommens JM, Kerem B. et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 1989; 245 (4922): 1066-1073
• 2 Southern KW, Munck A, Pollitt R. et al; ECFS CF Neonatal Screening Working Group. A survey of newborn screening for cystic fibrosis in Europe. J Cyst Fibros 2007; 6 (01) 57-65
• 3 Zielenski J. Genotype and phenotype in cystic fibrosis. Respiration 2000; 67 (02) 117-133
• 4 Cystic Fibrosis Mutation Database. Accessed August 2, 2019 at: http://www.gent.sickkids.on.ca/cftr
• 5 Kanavakis E, Efthymiadou A, Strofalis S, Doudounakis S, Traeger-Synodinos J, Tzetis M. Cystic fibrosis in Greece: molecular diagnosis, haplotypes, prenatal diagnosis and carrier identification amongst high-risk individuals. Clin Genet 2003; 63 (05) 400-409
• 6 Loukas YL, Thodi G, Molou E, Georgiou V, Dotsikas Y, Schulpis KH. Clinical diagnostic Next-Generation sequencing: the case of CFTR carrier screening. Scand J Clin Lab Invest 2015; 75 (05) 374-381
• 7 Brass EP. Pivalate-generating prodrugs and carnitine homeostasis in man. Pharmacol Rev 2002; 54 (04) 589-598
• 8 Reuter SE, Evans AM. Carnitine and acylcarnitines: pharmacokinetic, pharmacological and clinical aspects. Clin Pharmacokinet 2012; 51 (09) 553-572
• 9 Jeukendrup AE, Saris WH, Wagenmakers AJ. Fat metabolism during exercise: a review. Part I: fatty acid mobilization and muscle metabolism. Int J Sports Med 1998; 19 (04) 231-244
• 10 Shortland GJ, Walter JH, Stroud C, Fleming PJ, Speidel BD, Marlow N. Randomised controlled trial of L-carnitine as a nutritional supplement in preterm infants. Arch Dis Child Fetal Neonatal Ed 1998; 78 (03) F185-F188
• 11 Campoy C, Liemlahi S, Rivero M, López C, Bayés R. Capacity for fatty acid oxidation in the neonatal period. Prenat Neonatal Med 1996; 1: 366
• 12 Rebouche CJ. Carnitine function and requirements during the life cycle. FASEB J 1992; 6 (15) 3379-3386
• 13 Lloyd-Still JD, Bohan T, Hughes S, Wessel HU. Acylcarnitine is low in cord blood in cystic fibrosis. Acta Paediatr Scand 1990; 79 (04) 427-430
• 14 Lloyd-Still JD, Powers CA, Wessel HU. Carnitine metabolites in infants with cystic fibrosis: a prospective study. Acta Paediatr 1993; 82 (02) 145-149
• 15 Loukas YL, Soumelas GS, Dotsikas Y. et al. Expanded newborn screening in Greece: 30 months of experience. J Inherit Metab Dis 2010; 33 (Suppl. 03) S341-S348
• 16 Shekhawat PS, Sonne S, Carter AL, Matern D, Ganapathy V. Enzymes involved in L-carnitine biosynthesis are expressed by small intestinal enterocytes in mice: implications for gut health. J Crohn's Colitis 2013; 7 (06) e197-e205
• 17 Stanley CA. Carnitine deficiency disorders in children. Ann N Y Acad Sci 2004; 1033: 42-51
• 18 Mamedov I, Zolkina I, Nikolaeva E, Glagovsky P, Sukhorukov V. Carnitine insufficiency in children with inborn errors of metabolism: prevalence and treatment efficacy. J Pediatr Endocrinol Metab 2015; 28 (11-12): 1299-1304
• 19 Crill CM, Helms RA. The use of carnitine in pediatric nutrition. Nutr Clin Pract 2007; 22 (02) 204-213
• 20 Li L, Somerset S. Digestive system dysfunction in cystic fibrosis: challenges for nutrition therapy. Dig Liver Dis 2014; 46 (10) 865-874
• 21 Durieu I, Josserand RN. [Cystic fibrosis in 2008]. Rev Med Interne 2008; 29 (11) 901-907
• 22 De Lisle RC, Borowitz D. The cystic fibrosis intestine. Cold Spring Harb Perspect Med 2013; 3 (09) a009753
• 23 Cipolli M, Castellani C, Wilcken B. et al. Pancreatic phenotype in infants with cystic fibrosis identified by mutation screening. Arch Dis Child 2007; 92 (10) 842-846
• 24 Borowitz D, Robinson KA, Rosenfeld M. et al; Cystic Fibrosis Foundation. Cystic Fibrosis Foundation evidence-based guidelines for management of infants with cystic fibrosis. J Pediatr 2009; 155 (6, Suppl) S73-S93
• 25 Njoroge SW, Laposata M, Katrangi W, Seegmiller AC. DHA and EPA reverse cystic fibrosis-related FA abnormalities by suppressing FA desaturase expression and activity. J Lipid Res 2012; 53 (02) 257-265
• 26 Van Biervliet S, Van Biervliet JP, Robberecht E, Christophe A. Fatty acid composition of serum phospholipids in cystic fibrosis (CF) patients with or without CF related liver disease. Clin Chem Lab Med 2010; 48 (12) 1751-1755
• 27 Meyburg J, Schulze A, Kohlmueller D. et al. Acylcarnitine profiles of preterm infants over the first four weeks of life. Pediatr Res 2002; 52 (05) 720-723
• 28 Clark RH, Kelleher AS, Chace DH, Spitzer AR. Gestational age and age at sampling influence metabolic profiles in premature infants. Pediatrics 2014; 134 (01) e37-e46
• 29 Storni V, Clausters M, Chinet T, Ravilly S. Diagnostic de la mucoviscidose. Arch Pediatr 2001; 8: 818-832
• 30 Kalivianakis M, Minich DM, Bijleveld CM. et al. Fat malabsorption in cystic fibrosis patients receiving enzyme replacement therapy is due to impaired intestinal uptake of long-chain fatty acids. Am J Clin Nutr 1999; 69 (01) 127-134
• 31 Peretti N, Roy CC, Drouin E. et al. Abnormal intracellular lipid processing contributes to fat malabsorption in cystic fibrosis patients. Am J Physiol Gastrointest Liver Physiol 2006; 290 (04) G609-G615
• 32 Novak M, Monkus EF, Chung D, Buch M. Carnitine in the perinatal metabolism of lipids. I. Relationship between maternal and fetal plasma levels of carnitine and acylcarnitines. Pediatrics 1981; 67 (01) 95-100
• 33 Penn D, Dolderer M, Schmidt-Sommerfeld E. Carnitine concentrations in the milk of different species and infant formulas. Biol Neonate 1987; 52 (02) 70-79
• 34 Scaglia F, Longo N. Primary and secondary alterations of neonatal carnitine metabolism. Semin Perinatol 1999; 23 (02) 152-161
• 35 Kepka A, Minarowska A, Minarowski L. et al. Serum and urinary carnitine in children with cystic fibrosis. Prog Health Sci 2013; 3: 13-18
• 36 Giovannini M, Agostoni C, Salari PC. Is carnitine essential in children?. J Int Med Res 1991; 19 (02) 88-102
• 37 Engelen MP, Com G, Deutz NE. Protein is an important but undervalued macronutrient in the nutritional care of patients with cystic fibrosis. Curr Opin Clin Nutr Metab Care 2014; 17 (06) 515-520
• 38 Colombo C, Costantini D, Zazzeron L. et al. Benefits of breastfeeding in cystic fibrosis: a single-centre follow-up survey. Acta Paediatr 2007; 96 (08) 1228-1232
• 39 Jadin SA, Wu GS, Zhang Z. et al. Growth and pulmonary outcomes during the first 2 y of life of breastfed and formula-fed infants diagnosed with cystic fibrosis through the Wisconsin Routine Newborn Screening Program. Am J Clin Nutr 2011; 93 (05) 1038-1047